Back

Physicians’ Education Resource

  • BCG Vaccine
  • Non-Muscle Invasive Bladder Neoplasms

Medical Crossfire(R): Breakthroughs in Non-Muscle-Invasive Bladder Cancer: Advancing Patient Care Through Innovation in Treatment

Non muscle-invasive bladder cancer (NMIBC) represents the majority of newly-diagnosed bladder cancers, and it remains associated with high rates of recurrence and progression despite standard therapies. Management is increasingly complex due to ongoing shortages of Bacillus Calmette-Guerin vaccine, limited durability of conventional intravesical treatments, and the rapid emergence of novel immunotherapies, gene therapies, and advanced drug-delivery platforms. Clinicians continue to face challenges in risk stratification, treatment sequencing, and integrating newly approved and investigational agents into personalized care plans. This continuing medical education certified program is delivered using the Medical Crossfire format, which leverages expert debate and multidisciplinary discussion to translate emerging clinical data into practical, real-world decision-making. The virtual format enables broad participation by urologists, medical oncologists, and advanced practice providers and facilitates timely education and interactive exchange on evolving NMIBC treatment strategies without geographic barriers.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME · seen on gotoper.com

  • Enduring / On-demand
  • Credit · Up to 1.5 credits
  • Commercial Support
  • Released
    Mar 24, 2026
  • Last day to claim credit
    Mar 25, 2027 5 months left